(AIM: SAR)

26 November 2014

SAREUM HOLDINGS PLC

(“Sareum” or the “Company”)

Issue of Options

The Company announces that it has granted the following share options (the “Options”) to Tim Mitchell, Chief Executive Officer, John Reader, Chief Scientific Officer and Paul Harper, Non-Executive Chairman;

 

Number of options

Tim Mitchell

7,198,353

John Reader

7,198,353

Paul Harper

1,227,059

The Options have been granted with an exercise price of 0.425 pence and are exercisable until 25 November 2024. The Options will vest subject to pre-determined performance criteria.

In addition to the Options being granted, Tim Mitchell and John Reader currently each hold the following options:

Exercise period

Number of options

Exercise price

4 December 2009 - 4 December 2019

6,400,000

0.25 pence

22 December 2010 - 22 December 2020

6,153,846

0.26 pence

13 March 2012 - 13 March 2022

2,566,666

1.2 pence

18 December 2013 – 18 December 2023

4,752,000

0.6 pence

In addition to the Options being granted, Paul Harper holds the following options:

Exercise period

Number of options

Exercise price

18 December 2013 – 18 December 2023

810,000

0.6 pence

Enquires:

Sareum Holdings plc

 

Tim Mitchell, Chief Executive Officer

01223 497 700

Sanlam Securities UK Limited (Nominated Adviser)

 

Simon Clements / James Thomas

020 7628 2200

Hybridan LLP (Broker)

 

Claire Noyce / William Lynne

0203 713 4581/ 4582

The Communications Portfolio (Media enquiries)

 

Ariane Comstive
ariane.comstive@communications-portfolio.co.uk

020 7536 2028 / 2029

Notes for editors:

About Sareum Holdings plc

Sareum is a drug discovery and development company delivering targeted small molecule therapeutics, focusing on cancer and autoimmune disease, for licensing to pharmaceutical and biotechnology companies at the pre-clinical or early clinical trials stage.

Sareum operates an outsourced research model, working with collaborators (SRI International, the CRT Pioneer Fund and Hebei Medical University Biomedical Engineering Center) and a world-wide network of research providers. Its research pipeline includes two programmes undergoing pre-clinical IND-enabling studies.

SKIL® (Sareum Kinase Inhibitor Library) is Sareum's drug discovery technology platform that has so far produced the Company's Aurora+FLT3, Aurora+ALK, VEGFR-3, FLT3 & TYK2 kinase cancer and auto-immune disease research programmes. SKIL® can also generate drug research programmes against other kinase targets.

For further information, please visit www.sareum.co.uk